Kala Pharmaceuticals, Inc. Announces Executive Appointments
May 09, 2018 at 05:05 pm
Share
Kala Pharmaceuticals, Inc. announced the following key commercial hires in preparation for the potential approval and launch of INVELTYSTM: Kathleen McCann Kline as Vice President of Marketing, James Patnoe as Vice President of Commercial Operations and Pricing; Carl Rennie as Executive Director of Account Management, Patrick Bedell as Executive Director of Trade and Alternate Channels and Lynette Zickl as Director of Commercial Analytics and Forecasting. Ms. Kline has joined Kala Pharmaceuticals as Vice President of Marketing. Most recently, she served as Vice President of Marketing for the Ophthalmology and Women’s Health divisions at Bausch and Lomb where she was instrumental in leading the strategic initiatives supporting numerous surgical and pharmaceutical franchises, including intraocular lenses, surgical equipment and the Loteprednol franchise. Mr. Patnoe has joined Kala Pharmaceuticals as Vice President of Commercial Operations and Pricing. Previously, he served as Vice President of Sales Operations, Contracts and Pricing at Takeda Pharmaceuticals America, where he spent 10 years in roles of increasing responsibility, including Vice President of Managed Markets. Mr. Rennie has joined Kala Pharmaceuticals as Executive Director of Account Management. Prior to Kala, he was the Director of National Accounts for Collegium Pharmaceuticals. Mr. Bedell has joined Kala Pharmaceuticals as Executive Director of Trade and Alternate Channels. Most recently, he was Senior Director of Trade and Alternate Channels for Collegium Pharmaceuticals. Ms. Zickl has joined Kala Pharmaceuticals as Director of Commercial Analytics and Forecasting. Previously, she was Head of Insights and Analytics for scPharmaceuticals, where she led the Commercial Analytics and Operations build-out and helped the company transition from Series A to a publicly-traded company.
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Companyâs biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Companyâs product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.